🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluation of the Osteointegrative and Regenerative Capacity of a Scaffold Enriched With Bone Marrow-Derived Cells at the Subchondral Level, Associated With Retrograde Drilling

RecruitingNAAges 18 Years - 55 YearsAllIstituto Ortopedico Rizzoli
NCT07555899 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Osteochondral lesions of the ankle (OsteoChondral Lesions - OCLs) are defects of the subchondral bone and the overlying articular cartilage that commonly affect young and active patients. The main symptoms include chronic ankle pain, recurrent swelling, stiffness, and instability. The ideal treatment for OCLs remains a matter of debate. Various surgical techniques have been proposed, both arthroscopic and open. The choice of treatment depends on several factors, including lesion pathology, patient characteristics, and surgeon preference. In the presence of subchondral cysts or lesions with intact and stable cartilage surfaces, retrograde drilling is among the most commonly used techniques. This is a reparative, extra-articular procedure that reaches the lesion via a retrograde approach, thereby preventing iatrogenic cartilage damage. The surgical technique involves creating multiple cha

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
All patients diagnosed with subchondral cysts with intact cartilage or massive osteochondral lesions (OCLs) of the ankle joint treated with retrograde drilling and application of bone marrow aspirate on a scaffold at the First Clinic of the Rizzoli Orthopaedic Institute in Bologna will be included, in accordance with the criteria specified below. INCLUSION CRITERIA: Patients with one or more chronic cystic subchondral lesions of the talus (Grade IIA according to the Giannini classification); Patients with one or more chronic subchondral lesions with intact cartilage or large chronic OCLs (Grade IIA according to the Giannini classification); Age ≥ 18 years and ≤ 55 years; Ankle pain with limitation in normal activities of daily living (American Orthopaedic Foot and Ankle Score - AOFAS \< 85, Short Form-36 - SF-36 \< 86); Patients able to provide written informed consent to participate in the study. EXCLUSION CRITERIA: Patients \< 18 years or \> 55 years of age; Presence of active infections at the time of study inclusion; Positive status for HIV, HBV, or HCV; Pregnancy; Patients with autoimmune or rheumatologic diseases; Disorders of the immune system; Presence of severe malalignment of the tibiotalar joint in the coronal plane, whether supra-, intra-, or infra-articular (distal tibial articular angle \< or \> 10°, talar tilt \> 8°, severe cavus or flatfoot); Any other condition or disease that contraindicates surgical treatment.
💊

What it tests

  • Osteochondral lesions treated with a scaffold enriched with bone marrow-derived cells at the subchondral level combined with retrograde drilling.
📍

Where

1 site
Istituto Ortopedico Rizzoli
Bologna, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy